Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Objective: To evaluate the role of CD24 expression regarding cisplatin sensitivity in head and neck squamous cell carcinoma (HNSCC) cell lines.
Design: Cell line study involving University of Michigan Squamous Cell Carcinoma (UM-SCC) cell lines.
Main Outcome Measures: Expression of membrane-bound CD24 was measured by flow cytometry in molecules of equivalent standard fluorochrome (MESF) units. Tumor cell viability in response to cisplatin was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay following CD24 RNA interference or CD24 up-regulation.
Kaczorowski A, Clay M, Brenner C, Bauer J, Carey TE, Bradford CR, Prince ME. P119 CD24 Expression Correlates With Response to Cisplatin in Head and Neck Squamous Cell Carcinoma Cell Lines. Arch Otolaryngol Head Neck Surg. 2006;132(8):888. doi:10.1001/archotol.132.8.888-b
Customize your JAMA Network experience by selecting one or more topics from the list below.